Plymouth Meeting, PA – April 14, 2016: CRF Health, the leading global provider of eCOA solutions for the life sciences industry, announces that its TrialMax platform has been adopted by a leading developer of therapeutics for respiratory disease conditions to support one of the largest recorded Phase III studies into chronic obstructive pulmonary disease (COPD). The trial, involving more than 19,000 patients, will use the TrialMax platform to deliver electronic versions of key COPD instruments, enabling investigators to monitor exacerbations, while making compliance as easy as possible for patients. COPD trials routinely face reduced compliance due to a patient population which must regularly complete patient reported outcomes while struggling with lowered energy levels. In this large scale global study, which will involve more than 900 clinical research sites in nearly 40 countries, the TrialMax solution will make data collection as efficient and unobtrusive as possible, driving the collection of a more complete data set through increased compliance. "Our TrialMax platform is designed to fit into patients' real lives to fuel high compliance, making it the ideal solution to overcome the adherence challenges that are prevalent in COPD trials, especially in a patient population of this size", said John Blakeley, Chief Business Officer at CRF Health. "We're delighted to be part of one of the largest recorded clinical studies of COPD and supporting research advancements that will result in better treatments for those living with the challenges associated with the condition." For further information on CRF Health, please visit www.crfhealth.com About CRF Health CRF Health is the leading provider of electronic Clinical Outcome Assessment (eCOA) solutions for global clinical trials. With experience in more than 800 trials, over 100 languages and across 74 countries, CRF Health’s TrialMax eCOA solutions consistently demonstrate the industry’s highest data accuracy, patient and site compliance, and patient retention. CRF Health’s TrialMax eCOA solutions improve trial engagement by fitting into the lives of patients and seamlessly integrating into sites to maximize protocol compliance. Their eCOA solutions include PROs (Patient Reported Outcomes), ObsROs (Observer Reported Outcomes) and ClinROs (Clinician or Rater Reported Outcomes).
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.